This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This rapid processing not only enhances throughput, but will also allow pharmaceuticalcompanies to respond more swiftly to market demands. Can pharma tariffs “Make America Manufacture Again”?
Zentiva Group has entered into a licence and supply agreement with pharmaceuticalcompany Lupin for the commercialisation of the latter’s biosimilar Certolizumab Pegol, a tumour necrosis factor alpha (TNFα) inhibitor medicine, across several markets. Stay proactive with real-time data and expert analysis.
It feels like in the US, pharmaceuticalcompanies are capitalising on people’s frustration and desperation to lose weight.” Trump’s ‘most favoured nation’ model comes at a time when the administration has been vocal on its support for generics and biosimilars – copycat drugs that offer patients a cheaper entry point to treatment.
Go deeper with GlobalData Reports Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzh. By GlobalData Learn more about Strategic Intelligence In light of the approvals of Leqembi and Kisunla, large pharmaceuticalcompanies are increasingly investing in Alzheimer’s disease through high-value acquisitions.
billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023. billion takeover bid for Verve Therapeutics, upgrading a collaboration between the two companies that dates back to 2023.
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content